Dr. David Meeker, CEO of Rhythm Pharma, says tariffs won't directly impact them but could stress the biotech sector. He warns FDA layoffs may slow drug approvals for rare diseases.
.
Health
Meeker: Tariffs won't hit us hard, but they pressure the whole sector

Dr. David Meeker, CEO of Rhythm Pharma, says tariffs won't directly impact them but could stress the biotech sector. He warns FDA layoffs may slow drug approvals for rare diseases.